{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:12:33Z","timestamp":1770678753121,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,15]],"date-time":"2015-03-15T00:00:00Z","timestamp":1426377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jphs.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T17:33:09Z","timestamp":1428255189000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice"],"prefix":"10.1016","volume":"127","author":[{"given":"Saki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2015.03.004_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.arr.2014.03.008","article-title":"Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes","volume":"15","author":"Silva","year":"2014","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jphs.2015.03.004_bib2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/gps.448","article-title":"Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study","volume":"16","author":"Lyketsos","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000110738","article-title":"Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I","volume":"24","author":"Aalten","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jphs.2015.03.004_bib4","first-page":"215","article-title":"Pharmacological treatment of behavioral symptoms in dementia patients","volume":"71","author":"Gabryelewicz","year":"2014","journal-title":"Przegl Lek"},{"key":"10.1016\/j.jphs.2015.03.004_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0166-2236(91)90117-D","article-title":"Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence","volume":"14","author":"Fibiger","year":"1991","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jphs.2015.03.004_bib6","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/S0024-3205(01)01055-4","article-title":"Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism","volume":"68","author":"Salamone","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.jphs.2015.03.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.745","article-title":"Pharmacological management of behavioural and psychological disturbance in dementia","volume":"21","author":"Kozman","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","article-title":"Combination therapy in Alzheimer's disease: a review of current evidence","volume":"18","author":"Schmitt","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jphs.2015.03.004_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jphs.2015.03.004_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jphs.2015.03.004_bib11","first-page":"213","article-title":"Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone","volume":"49","author":"Ohno","year":"1997","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia","volume":"52","author":"Kapur","year":"2001","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jphs.2015.03.004_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1755-5949.2010.00211.x","article-title":"Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease","volume":"17","author":"Ohno","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jphs.2015.03.004_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/18715273113129990088","article-title":"Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions","volume":"12","author":"Shimizu","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jphs.2015.03.004_bib16","first-page":"1","article-title":"Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT(1A) receptors","volume":"4","author":"Shimizu","year":"2013","journal-title":"Aging Dis"},{"key":"10.1016\/j.jphs.2015.03.004_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mds.22027","article-title":"Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains","volume":"23","author":"Smith","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.jphs.2015.03.004_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-004-2132-z","article-title":"Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model","volume":"180","author":"Van Dam","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jphs.2015.03.004_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00213-007-0962-1","article-title":"Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice","volume":"196","author":"Koda","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jphs.2015.03.004_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jphs.2015.03.004_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pnpbp.2012.04.008","article-title":"Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders","volume":"38","author":"Tatara","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0091-3057(94)90451-0","article-title":"Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test","volume":"49","author":"Ohno","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jphs.2015.03.004_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00169040","article-title":"Dopaminergic regulation of striatal cholinergic interneurons: an in\u00a0vivo microdialysis study","volume":"342","author":"Damsma","year":"1990","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0022-3565(25)12934-0","article-title":"Physiological release of striatal acetylcholine in\u00a0vivo: modulation by D1 and D2 dopamine receptor subtypes","volume":"277","author":"DeBoer","year":"1996","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2015.03.004_bib26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2015.03.004_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.11R01CR","article-title":"Pharmacological aspects of the acetylcholinesterase inhibitor galantamine","volume":"116","author":"Ago","year":"2011","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2015.03.004_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1440-1819.2011.02253.x","article-title":"New drugs for Alzheimer's disease in Japan","volume":"65","author":"Takeda","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jphs.2015.03.004_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002512-200118120-00001","article-title":"Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?","volume":"18","author":"Giacobini","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jphs.2015.03.004_bib30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/syn.20969","article-title":"Donepezil, but not galantamine, blocks muscarinic receptor-mediated in\u00a0vitro and in\u00a0vivo responses","volume":"65","author":"Ago","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.jphs.2015.03.004_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0891-0618(00)00092-2","article-title":"Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression","volume":"21","author":"Neumaier","year":"2001","journal-title":"J\u00a0Chem Neuroanat"},{"key":"10.1016\/j.jphs.2015.03.004_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2004.01.031","article-title":"8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents","volume":"487","author":"Hedlund","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.pnpbp.2008.04.005","article-title":"Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test","volume":"32","author":"Ohno","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2015.03.004_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-2999(96)00139-2","article-title":"Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum","volume":"303","author":"Ishibashi","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0306-3623(96)00056-0","article-title":"Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices","volume":"27","author":"Ishida","year":"1996","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.jphs.2015.03.004_bib37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jphs.2015.03.004_bib38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jphs.2015.03.004_bib39","series-title":"Antipsychotic drugs: pharmacology, side effects and abuse prevention","first-page":"323","article-title":"Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors","author":"Ohno","year":"2012"},{"key":"10.1016\/j.jphs.2015.03.004_bib40","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T22:34:48Z","timestamp":1747866888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861315000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1347861315000602"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2015.03.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}